Better Medicine
for a Brighter Tomorrow
‘Sol’ means the Sun and
‘Asia’ the Asian counties in Spanish.
We desire to be the Sun brightening the future of
various people facing many challenges of
cancers in Japan and other Asian countries.
Solasia
at a Glance
PIPELINES | INDICATION | AREA | PRE- CLINICAL |
CLINIAL STUDY | NDA | APPROVAL /LAUNCH |
PROGRESS | PARTNER | ||
---|---|---|---|---|---|---|---|---|---|---|
PHASE 1 | PHASE 2 | PHASE 3 | ||||||||
Sancuso®(SP-01) MORE INFO |
Chemotherapy Induced Nausea and Vomiting (CINV) | China |
|
|
|
|
|
|
Launched in 2019 Preparing to apply for change of manufacturing facility |
Lee’s Pharm: |
DARVIAS® (SP-02) MORE INFO |
Peripheral T-Cell Lymphoma (PTCL) | Japan |
|
|
|
|
|
|
Launched in August 2022 Began searching for additional indications | Nippon Kayaku:
|
South Korea, Taiwan, Hong Kong |
|
|
|
|
|
|
Phase II (pivotal) study completed Out-licensing activities ongoing | |||
South America |
|
|
|
|
|
|
Preparations to file for approval underway in each country based on approval granted in Japan(Colombia has already filed.) | |||
China |
|
|
|
|
|
|
Development strategy being drafted based on US study data and approval in Japan; out-licensing activity ongoing | |||
US |
|
|
|
|
|
|
Early Phase II study completed; out-licensing activity ongoing | |||
EU |
|
|
|
|
|
|
NPP strategy being launched | |||
episil® oral liquid(SP-03) MORE INFO |
Pain associated oral mucositis [Medical Device] | Japan |
|
|
|
|
Launched in 2018 | Meiji Seika Pharma: Japan
Lee’s Pharm:
Synex: |
||
China |
|
|
|
|
Launched in 2019 | |||||
South Korea |
|
|
|
|
Launched in 2020 |
PIPELINES | TARGET INDICATION |
AREA | PRE- CLINICAL |
CLINIAL STUDY | NDA | APPROVAL /LAUNCH |
PROGRESS | PARTNER | ||
---|---|---|---|---|---|---|---|---|---|---|
PHASE 1 | PHASE 2 | PHASE 3 | ||||||||
SP-04 MORE INFO |
Chemotherapy Induced Peripheral Neuropathy (CIPN) | Japan etc. |
|
|
|
|
|
|
Pre-clinical study in taxane-induced peripheral neuropathy | Maruho: |
SP-05 MORE INFO |
Colorectal Cancer (CRC) | Japan |
|
|
|
|
|
|
Decision to resume development. | ー |